Resveratrol regulates p66Shc activation in HaCaT cells

Experimental Dermatology

Volumn 19, Issue 10, 2010, Pages 895-903

  Fabbrocini, Gabriella ^a   Kisslinger, Annamaria ^b   Iannelli, Paola ^a   Vitale, Nicoletta ^c   Procaccini, Claudio ^b   Sparaneo, Giuseppina ^a   Chieffi, Paolo ^d   Ayala, Fabio ^a   Mancini, Francesco Paolo ^a,c   Tramontano, Donatella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF SANNIO   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTIOXIDANT; ENZYME INHIBITOR; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRILE; PROTEIN KINASE B; PROTEIN SHC; RESVERATROL; SHC1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

ARTICLE; CELL DEATH; CELL DIVISION; CELL LINE; CYTOLOGY; DRUG EFFECT; HUMAN; KERATINOCYTE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; BUTADIENES; CELL DEATH; CELL DIVISION; CELL LINE, TRANSFORMED; ENZYME INHIBITORS; HUMANS; KERATINOCYTES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SHC SIGNALING ADAPTOR PROTEINS; STILBENES;

EID: 78650826947     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01117.x     Document Type: Article

References (69)

1. Bickers D R, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 2006: 126: 2565-2575.
2. Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 2009: 47: 891-905. Review.
3. Trachootham D, Lu W, Ogasawara M A, Nilsa R D, Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008: 10: 1343-1374.
4. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 2008: 10: 475-510.
5. Finkel T. Ageing: a toast to long life. Nature 2003: 425: 132-133.
6. Sofi F, Cesari F, Abbate R, Gensini G F, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008: 337: 1344-1351.
7. Pervaiz S, Holme A L et al. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009: 11: 2851-2897.
8. Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 2009: 10: 530-546.
9. Knutson M D, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 2008: 66: 591-596.
10. Jang M, Cai L, Udeani G O, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997: 275: 218-20.
11. Reagan-Shaw S, Afaq F, Aziz M H, Ahmad N. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene 2004: 23: 5151-5160.
12. Kim Y A, Rhee S H, Park K Y, Choi Y H. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food 2003: 6: 273-280.
13. Kim Y A, Choi B T, Lee Y T et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep 2004: 11: 441-446.
14. Kim Y A, Lee W H, Choi T H, et al. Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in humanlung carcinoma A549 cells. Int J Oncol 2003: 23: 1143-1149.
15. Ahmad N, Adhami V M, Afaq F, Feyes D K, Mukhtar H. Reveratrol causes WAF-1/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001: 7: 1466-1473.
16. Campos-Toimil M, Elíes J, Alvarez E, Verde I, Orallo F. Effects of trans- and cis-resveratrol on Ca2+ handling in A7r5 vascular myocytes. Eur J Pharmacol 2007: 577: 91-99.
17. Gehm B D, McAndrews J M, Chien P Y, Jameson J L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 1997: 94: 14138-14143.
18. Belleri M, Ribatti D, Savio M et al. alphavbeta3integrin-dependent antiangiogenic activity of resveratrol stereoisomers. Mol Cancer Ther 2008: 7: 3761-3770.
19. Baur J A, Pearson K J, Price N L et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006: 444: 337-342.
20. Pfluger P T, Herranz D, Velasco-Miguel S, Serrano M, Tshop M H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008: 105: 9793-9798.
21. Gadacha W, Ben-Attia M, Bonnefont-Rousselot D, Aouani E, Ghanem-Boughanmi N, Touitou Y. Resveratrol opposite effects on rat tissue lipoperoxidation:pro-oxidant during day-time and antioxidant at night. Redox Rep 2009: 14: 154-158.
22. Russo G L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 2007: 74: 533-544.
23. De La Lastra C A, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007: 35: 1156-1160.
24. Fulda S, Debatin K-M. Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review. Cancer Detect Prev 2006: 30: 217-233.
25. Kundu J K, Surh Y J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008: 269: 243-261.
26. Rajendran M, Thomes P, Zhang L, Veeramani S, Lin M F. p66Shc-a longevity redox protein in human prostate cancer progression and metastasis: p66Shc in cancer progression and metastasis. Cancer Metastasis Rev 2010: 29: 207-222.
27. Shc deletion in age-associated arterial dysfunction and disease states. J Appl Physiol 2008: 105: 1628-1631.
28. Sansone P, Storci G, Giovannini C et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007: 25: 807-815.
29. 2+ homeostasis. Cell Death Differ 2007: 14: 338-347.
30. Petti L M, Ricciardi E C, Page H J, Porter K A. Transforming signals resulting from sustained activation of PDGFβ receptor in mortal human fibroblasts. J Cell Sci 2008: 121: 1172-1182.
31. Alam S M, Rajendran M, Ouyang S, Veeramani S, Zhang L O, Lin M F. A novel role of Shc adaptor proteins in steroid hormone-regulated cancers. Endocr Relat Cancer 2009: 16: 1-16.
32. Guo J, Gertsberg Z, Ozgen N, Steinberg S F. p66Shc links alpha1-adrenergic receptors to a reactive oxygen species-dependent AKT-FOXO3A phosphorylation pathway in cardiomyocytes. Circ Res 2009: 104: 660-669.
33. Percy C J, Brown L, Power D A, Johnson D W, Gobe G C. Obesity and hypertension have differing oxidant handling molecular pathways in age-related chronic kidney disease. Mech Ageing Dev 2009: 130: 129-38.
34. Bonafè M, Olivieri F. Genetic polymorphism in long-lived people: cues for the presence of an insulin/IGF-pathway-dependent network affecting human longevity. Mol Cell Endocrinol 2009: 299: 118-123.
35. Pani G, Koch O R, Galeotti T. The p53-p66shc-Manganese Superoxide Dismutase (MnSOD) network: a mitochondrial intrigue to generate reactive oxygen species. Int J Biochem Cell Biol 2009: 41: 1002-1005.
36. Capitani N, Lucherini O M, Sozzi E, et al. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. Blood 2010: 115: 3726-3736.
37. Arany I, Faisal A, Nagamine Y, Safirstein R L. p66shc inhibits pro-survival epidermal growth factor receptor/ERK signaling during severe oxidative stress in mouse renal proximal tubule cells. J Biol Chem 2008: 283: 6110-6117.
38. Berniakovich I, Trinei M, Stendardo M, et al. p66Shc-generated oxidative signal promotes fat accumulation. J Biol Chem 2008: 283: 34283-93.
39. Tomilov A A, Bicocca V, Schoenfeld R A, et al. Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice. J Biol Chem 2010: 285: 1153-65.
40. Chahdi A, Sorokin A. Endothelin-1 couples betaPix to p66Shc: role of betaPix in cell proliferation through FOXO3a phosphorylation and p27kip1 down-regulation independently of Akt. Mol Biol Cell 2008: 19: 2609-2619.
41. Sadruddin S, Arora R. Resveratrol: biologic and therapeutic implications. J Cardiometab Syndr 2009: 4: 102-106.
42. Athar M, Back J H, Kopelovich L, Bickers D R, Kim A L. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 2009: 486: 95-102.
43. Micallef L, Belaubre F, Pinon A et al. Effects of extracellular calcium on the growth-differentiation switch in immortalized keratinocyte HaCaT cells compared with normal human keratinocytes. Exp Dermatol 2009: 18: 143-151.
44. Deyrieux A F, Wilson V G. In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line. Cytotechnology 2007: 54: 77-83.
45. Humphries M J. Cell adhesion assays. Mol Biotechnol 2001: 18: 57-61.
46. Hu Y, Wang X, Zeng L. ERK phosphorylates p66ShcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. Mol Biol Cell 2005: 16: 3705-3718.
47. Yang C P, Horwitz S B. Distinct mechanisms of taxol-induced serine phosphorylation of the 66-kDa Shc isoform in A549 and RAW 264.7 cells. Biochim Biophys Acta 2002: 1590: 76-83.
48. Graf R, Kock M, Bock A et al. Lipophilic prodrugs of amino acids and vitamin E as osmolytes for the compensation of hyperosmotic stress in human keratinocytes. Exp Dermatol 2009: 18: 370-377.
49. Balmanno K, Cook S J. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009: 16: 368-377.
50. Tan A H, Lam K P. Pharmacologic Inhibition of MEK-ERK Signaling Enhances Th17 Differentiation. J Immunol 2010: 184: 1849-1857.
51. Bollag W B, Zhong X, Dodd M E, Hardy D M, Zheng X, Allred W T. Phospholipase d signaling and extracellular signal-regulated kinase-1 and -2 phosphorylation (activation) are required for maximal phorbol ester-induced transglutaminase activity, a marker of keratinocyte differentiation. J Pharmacol Exp Ther 2005: 312: 1223-1231.
52. McCubrey J A, Steelman L S, Chappell W H et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007: 177: 1263-1284. Review.
53. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007: 26: 3227-3239.
54. Gniadecki R. Activation of Raf-mitogen-activated protein kinase signaling pathway by 1, 25 dihydroxyvitamin D3 in normal human keratinocytes. J Invest Dermatol 1996: 106: 1212-1217.
55. Haase I, Hobbs R M, Romero M R, Broad S, Watt F M. A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis. J Clin Invest 2001: 108: 527-536.
56. Schmidt M, Goebeler M, Posern G et al. Ras-independent activation of the Raf/MEK/ERK pathway upon calcium-induced differentiation of keratinocytes. J Biol Chem 2000: 275: 41011-41017.
57. Robitaille H, Simard-Bisson C, Larouche D, Tanguay R M, Blouin R, Germain L. The small heat-shock protein Hsp27 undergoes ERK-dependent phosphorylation andredistribution to the cytoskeleton in response to dual leucine zipper-bearing kinase expression. J Invest Dermatol 2010: 130: 74-85.
58. Lee E R, Kang Y J, Kim J H, Lee H T, Cho S G. Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem 2005: 280: 31498-31507.
59. Lin H Y, Tang H Y, Keating T et al. Resveratrol is proapoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ER mediated. Carcinogenesis 2008: 29: 62-69.
60. Lee K W, Kang N J, Rogozin E A et al. The resveratrol analogue 3, 5, 3', 4', 5'-pentahydroxy-trans-stilbene inhibits cell transformation via MEK. Int J Cancer 2008: 123: 2487-2496.
61. Alkhalaf M. Resveratrol-induced growth inhibitionin MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation. Eur J Cancer Prev 2007: 16: 334-341.
62. El-Mowafy A M, Alkhalaf M, Nassar N N. Resveratrol reverses ET-1-evoked mitogenic effects in human coronary arterial cells by activating the kinase-G to inhibit ERK-enzymes. Int J Cardiol 2009: 136: 263-269.
63. Blander G, Bhimavarapu A, Mammone T et al. SIRT1 promotes differentiation of normal human keratinocytes. J Invest Dermatol 2009: 129: 41-49.
64. Sheng S, Qiao M, Pardee A B. Metastasis and AKT activation. J Cell Physiol 2009: 218: 451-454.
65. Garcia-Echeverria C, Sellers W R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008: 27: 5511-5526.
66. Smith W W, Norton D D, Gorospe M et al. Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. J Cell Biol 2005: 169: 331-339.
67. Migliaccio E, Giorgio M, Pelicci P G. Apoptosis and aging: role of p66Shc redox protein. Antioxid Redox Signal 2006: 8: 600-608.
68. Abd Elmageed Z Y, Gaur R L, Williams M et al. Characterization of coordinated immediate responses by p16INK4A and p53pathways in UVB-irradiated human skin cells. J Invest Dermatol 2009: 129: 175-183.
69. Favetta L A, St John E J, King W A, Betts D H. High levels of p66shc and intracellular ROS in permanently arrested early embryos. Free Radic Biol Med 2007: 42: 1201-1210.